ZA201901740B - Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof - Google Patents

Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof

Info

Publication number
ZA201901740B
ZA201901740B ZA201901740A ZA201901740A ZA201901740B ZA 201901740 B ZA201901740 B ZA 201901740B ZA 201901740 A ZA201901740 A ZA 201901740A ZA 201901740 A ZA201901740 A ZA 201901740A ZA 201901740 B ZA201901740 B ZA 201901740B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
receptor antagonist
mineralocorticoid receptor
mineralocorticoid
antagonist
Prior art date
Application number
ZA201901740A
Other languages
English (en)
Inventor
Zhenhua Huang
Xiaocui Guo
Original Assignee
Kbp Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61689352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201901740(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kbp Biosciences Co Ltd filed Critical Kbp Biosciences Co Ltd
Publication of ZA201901740B publication Critical patent/ZA201901740B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA201901740A 2016-09-24 2019-03-20 Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof ZA201901740B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610849142 2016-09-24
PCT/CN2017/102969 WO2018054357A1 (zh) 2016-09-24 2017-09-22 含盐皮质激素受体拮抗剂的药物组合物及其用途

Publications (1)

Publication Number Publication Date
ZA201901740B true ZA201901740B (en) 2019-10-30

Family

ID=61689352

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA201901740A ZA201901740B (en) 2016-09-24 2019-03-20 Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof

Country Status (29)

Country Link
US (2) US11806344B2 (enExample)
EP (1) EP3517113A4 (enExample)
JP (2) JP7090599B2 (enExample)
KR (1) KR102226516B1 (enExample)
CN (1) CN109069502B (enExample)
AU (1) AU2017329549B2 (enExample)
BR (1) BR112019005214A2 (enExample)
CA (1) CA3037588C (enExample)
CL (1) CL2019000753A1 (enExample)
CO (1) CO2019003808A2 (enExample)
CR (2) CR20190203A (enExample)
CU (1) CU24569B1 (enExample)
DO (1) DOP2019000072A (enExample)
EA (1) EA201990668A1 (enExample)
EC (1) ECSP19027578A (enExample)
IL (1) IL265560B (enExample)
MA (1) MA45202B1 (enExample)
MX (1) MX391602B (enExample)
MY (1) MY195054A (enExample)
NZ (1) NZ751901A (enExample)
PE (1) PE20190608A1 (enExample)
PH (1) PH12019500516A1 (enExample)
RU (2) RU2725153C1 (enExample)
SG (1) SG10201912389WA (enExample)
TN (1) TN2019000063A1 (enExample)
TW (2) TWI780488B (enExample)
UA (1) UA123464C2 (enExample)
WO (1) WO2018054357A1 (enExample)
ZA (1) ZA201901740B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123464C2 (uk) 2016-09-24 2021-04-07 Кейбіпі Байосайєнсіз Ко., Лтд. Фармацевтична композиція, яка містить антагоніст мінералокортикоїдних рецепторів, та її застосування
CN113425683B (zh) * 2021-08-19 2022-09-20 谢彩华 一种三氮脒缓释注射剂及其制备方法
CN116492336B (zh) * 2023-04-04 2024-07-05 迪沙药业集团有限公司 一种坎地沙坦酯药物组合物
CN120168468B (zh) * 2025-03-05 2025-10-17 苏州天马医药集团天吉生物制药有限公司 一种非奈利酮制剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
TWI431010B (zh) * 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
KR20210124532A (ko) * 2010-02-25 2021-10-14 브리스톨-마이어스 스퀴브 홀딩스 아일랜드 언리미티드 컴퍼니 아픽사반 제제
CN102372710A (zh) * 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 作为盐皮质激素受体拮抗剂的并环类化合物
CA2814371C (en) * 2010-10-29 2019-03-19 Algiax Pharmaceuticals Gmbh Use of malononitrilamides in neuropathic pain
AU2013362400B2 (en) * 2012-12-22 2016-07-28 Novo Nordisk A/S Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor
UA123464C2 (uk) 2016-09-24 2021-04-07 Кейбіпі Байосайєнсіз Ко., Лтд. Фармацевтична композиція, яка містить антагоніст мінералокортикоїдних рецепторів, та її застосування

Also Published As

Publication number Publication date
US20190201390A1 (en) 2019-07-04
NZ751901A (en) 2021-07-30
MA45202A1 (fr) 2020-11-30
TN2019000063A1 (en) 2020-07-15
HK1258622A1 (zh) 2019-11-15
EA201990668A1 (ru) 2019-10-31
EP3517113A4 (en) 2020-07-08
CA3037588A1 (en) 2018-03-29
BR112019005214A2 (pt) 2019-06-11
CN109069502B (zh) 2021-08-06
WO2018054357A1 (zh) 2018-03-29
DOP2019000072A (es) 2019-06-16
AU2017329549B2 (en) 2020-05-14
CR20240015A (es) 2024-04-05
EP3517113A1 (en) 2019-07-31
SG10201912389WA (en) 2020-02-27
UA123464C2 (uk) 2021-04-07
JP2019532939A (ja) 2019-11-14
CN109069502A (zh) 2018-12-21
CR20190203A (es) 2019-06-26
RU2725153C1 (ru) 2020-06-30
CO2019003808A2 (es) 2019-04-30
TW201813645A (zh) 2018-04-16
US20240016796A1 (en) 2024-01-18
TWI715806B (zh) 2021-01-11
JP2022037044A (ja) 2022-03-08
RU2020120876A3 (enExample) 2020-12-28
CU20190023A7 (es) 2019-11-04
PH12019500516A1 (en) 2020-02-24
IL265560A (en) 2019-05-30
CL2019000753A1 (es) 2019-07-19
MX2019003339A (es) 2019-06-03
ECSP19027578A (es) 2019-07-31
AU2017329549A1 (en) 2019-04-11
RU2750667C2 (ru) 2021-06-30
RU2020120876A (ru) 2020-08-26
KR102226516B1 (ko) 2021-03-12
TWI780488B (zh) 2022-10-11
MY195054A (en) 2023-01-05
US11806344B2 (en) 2023-11-07
TW202100156A (zh) 2021-01-01
JP7090599B2 (ja) 2022-06-24
PE20190608A1 (es) 2019-04-23
IL265560B (en) 2022-07-01
KR20190057323A (ko) 2019-05-28
CU24569B1 (es) 2022-01-13
MA45202B1 (fr) 2022-04-29
MX391602B (es) 2025-03-21
CA3037588C (en) 2022-07-12

Similar Documents

Publication Publication Date Title
ZA201808623B (en) Glucocorticoid receptor agonist and immunoconjugates thereof
ZA201802125B (en) Pharmaceutical composition and application thereof
IL247854A0 (en) Muscarinic receptor antagonists, preparations containing them and their uses
IL254552A0 (en) Polycyclic carbamoylpyridone compounds and their pharmaceutical uses
PT3606511T (pt) Composição farmacêutica compreendendo mesilato de lenvatinib
ZA201702813B (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
PT3421038T (pt) Compostos de naftiridina, combinações médicas e sua utilização
EP3728330A4 (en) PHARMACEUTICAL COMPOSITION OF CHEMICAL RECEPTOR AND ASSOCIATED PROCESS
IL265560A (en) Preparations containing a mineralocorticoid receptor antagonist and their uses
ZA201805496B (en) Somatostatin receptor antagonist compounds and methods of using the same
SG10202106375UA (en) Pharmaceutical compositions and use thereof
PL3288933T3 (pl) Związki oksindolowe i ich kompozycje farmaceutyczne
ZA201607353B (en) Bicyclic derivatives and pharmaceutical composition including the same
IL246629A0 (en) Pharmaceutical preparations containing a derivative of benzonitrile and gefitinib
ZA201903341B (en) Pharmaceutical compositions and uses thereof
GB201604810D0 (en) Pharmaceutical compositions and uses